Hims & Hers Health, Inc. (NYSE:HIMS) shares stumbled Friday afternoon. The company, the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications.

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate ...

Research reveals promising advancements of Ce6-GFFY in colorectal cancer treatment. Colorectal cancer (CRC) is a highly ...

A Potential Solution for Neurodegenerative Diseases. Open Access Library Journal, 12, 1-16. doi: 10.4236/oalib.1112714 . Alzheimer’s Disease (AD), a complex neurodegenerative condition, significantly ...

Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024. A transf ...